Published on

Toxicology: Zolpidem

BASICS

DESCRIPTION

Zolpidem is a short-acting sedative-hypnotic medication prescribed for the treatment of insomnia. Its main effect is to promote sleep by depressing activity within the central nervous system.


FORMS AND USES

Zolpidem has been marketed under the brand name Ambien and is available in several formulations, including immediate-release and extended-release preparations. The historical source described a typical adult oral dose of 10 mg; contemporary prescribed doses vary according to the formulation and individual patient factors.


TOXIC DOSE

A clearly defined toxic dose has not been established. Some isolated ingestions involving several times the prescribed daily amount have resulted in relatively mild central nervous system depression. However, the amount ingested alone cannot reliably predict severity, particularly when alcohol, opioids, or other sedating drugs are also involved.


PATHOPHYSIOLOGY

Zolpidem acts at the benzodiazepine-binding site of the GABA-A receptor complex, with relative selectivity for receptors involved in sedation. Enhancement of inhibitory signaling in the brain produces its hypnotic effects and, in overdose, may cause excessive drowsiness and impaired consciousness.


Fatal outcomes have been reported in cases involving zolpidem together with other central nervous system depressants, including combinations with carisoprodol, meprobamate, or other sedatives. Such reports demonstrate the importance of evaluating possible coingestants.


EPIDEMIOLOGY

Severe poisoning following exposure to zolpidem alone is relatively uncommon. Clinical presentations vary substantially according to the quantity taken and the presence of additional medications or alcohol.


CAUSES

Poisoning may follow accidental extra dosing, intentional self-poisoning, or simultaneous use of other sedating substances. A careful assessment of the circumstances is important, especially in pediatric exposures or when deliberate harm is suspected.


PREGNANCY AND LACTATION

The historical reference classified zolpidem as US FDA Pregnancy Category C. This letter-based classification system is no longer used in current US prescription labeling. Decisions about use during pregnancy or breastfeeding should instead consider contemporary medication-specific safety information, the clinical need for treatment, and possible effects on the infant.


DIAGNOSIS

SIGNS AND SYMPTOMS

Vital signs: Low blood pressure has been reported, more often when additional substances were ingested. An increased heart rate may also occur occasionally.


Eye findings: Pupil dilation (mydriasis) is possible but is not a common feature of zolpidem poisoning.


Cardiovascular effects: Tachycardia, bradycardia, and hypotension have been described but are relatively unusual in uncomplicated isolated exposures.


Respiratory effects: Serious respiratory depression is uncommon after isolated zolpidem ingestion, but its risk increases when zolpidem is combined with opioids, alcohol, or other central nervous system depressants.


Gastrointestinal effects: Nausea and vomiting may occur following ingestion.


Fluid, electrolyte, and kidney findings: Mild reductions in serum potassium and temporary increases in creatinine have occasionally been reported; these findings are not specific to zolpidem exposure.


Neurological effects: Drowsiness is the most frequent manifestation. Other possible symptoms include confusion, memory impairment, dizziness, incoordination or ataxia, and headache. Profound reductions in consciousness, including coma, have been described, sometimes without marked respiratory depression.


PROCEDURES AND LABORATORY TESTS

Essential Assessment

Routine laboratory investigations may not be required for an asymptomatic patient after a well-characterized, low-risk exposure. Clinical assessment should focus on mental status, breathing, circulation, and possible additional ingestions.


Recommended Investigations

Patients with altered consciousness may require measurement of blood glucose, electrolytes, blood urea nitrogen or urea, and creatinine, together with pulse oximetry and appropriate respiratory monitoring.


An electrocardiogram and serum acetaminophen and salicylate concentrations may help identify complications or unrecognized coingestants in an intentional or uncertain overdose.


Standard urine benzodiazepine immunoassays do not reliably detect zolpidem. When confirmation is clinically necessary, a specific analytical test may be required. A negative routine screening result therefore does not exclude zolpidem exposure.


If the cause of impaired consciousness remains unclear, additional investigations—such as brain imaging, infectious testing, or other evaluations—should be selected according to the clinical findings rather than attributed automatically to zolpidem.


TREATMENT

Management emphasizes airway protection, adequate ventilation, supportive care, and identification of other causes of central nervous system depression. Clinicians should determine the product, estimated quantity, time of ingestion, and any other medications or substances involved.


DIRECTING PATIENT CARE

Poison center consultation: Specialist advice is appropriate when symptoms are pronounced or persistent, coingestants are suspected, or underlying conditions and medication interactions complicate the presentation.


Referral to a healthcare facility: Emergency assessment is indicated for significant symptoms, possible self-harm, suspected deliberate poisoning of another person, or potentially dangerous mixed ingestions.


Admission considerations: Persistent sedation, impaired airway protection, respiratory compromise, or other serious abnormalities may require hospital admission. The historical source proposed admission when central nervous system depression persisted beyond a six-hour observation period, but current decisions should be individualized to the patient’s condition and exposure.


DECONTAMINATION

The historical source described gastric lavage and single-dose activated charcoal after substantial recent ingestions. These procedures are not routinely recommended for zolpidem poisoning, especially when the patient is sedated and aspiration is a concern. Any consideration of gastrointestinal decontamination should be made with a toxicology specialist and appropriate airway safeguards.


ANTIDOTES

Flumazenil may reverse some of zolpidem’s sedative effects, but it is not routinely used in overdose. It can provoke seizures or other complications in selected patients, especially when there is benzodiazepine dependence, a seizure risk, or a mixed ingestion involving proconvulsant drugs. Its use is reserved for carefully selected circumstances under expert supervision.


ADJUNCTIVE TREATMENT

Endotracheal intubation and assisted ventilation may be necessary if the patient cannot protect the airway or maintain adequate breathing. Additional treatment is guided by associated injuries, coingestants, and other complications.


FOLLOW-UP

PATIENT MONITORING

Patients with clinically important sedation require repeated assessment of consciousness, respiratory function, oxygenation, and cardiovascular status. Continuous monitoring may be needed until these findings normalize.


The historical reference suggested approximately six hours of observation after treatment. In practice, monitoring duration depends on the formulation taken, the clinical course, and whether other sedatives or extended-release products are involved.


EXPECTED COURSE AND PROGNOSIS

Symptoms generally begin within a relatively short time after ingestion and often improve as the drug is eliminated. Many uncomplicated exposures resolve within about a day, although recovery may be longer after large or mixed ingestions.


Full recovery is expected in most isolated cases when adequate supportive care is provided. Prolonged hypoxia or other serious complications can worsen the outcome.


DISCHARGE CRITERIA AND INSTRUCTIONS

Discharge may be considered once normal mental status, breathing, and vital signs have returned, clinically important coingestants have been excluded or managed, and further monitoring is unnecessary. Psychiatric assessment is appropriate when intentional self-poisoning is suspected.


PITFALLS IN DIAGNOSIS

A major diagnostic error is assuming zolpidem explains all altered mental status without evaluating for other potentially serious causes, such as hypoglycemia, head injury, stroke, infection, or exposure to additional sedative medications.


ICD-9-CM CLASSIFICATION

967 — Poisoning by sedatives and hypnotics (historical ICD-9-CM category).


Clinical note: This is a paraphrased educational article based on historical source material. The original pregnancy category, fixed observation period, decontamination procedures, and flumazenil dosing should not be treated as current emergency treatment protocols.



Image description
0 Comments